Whats exciting today is research showing that berberine works, in part, by supporting GLP-1 (glucagon-like peptide-1), the same pathway targeted by some of the most widely discussed metabolic medications
As in prior experiments with GEP44, no indicators of nausea or malaise (e.g., changes in responsiveness, behavior, coat appearance, or facial expressions such as orbital tightening and nose/cheek flattening) were observed with GEP12 dosing
doi: 10.3390/antiox12050988
Suspected side effects from medicines including those received as part of a clinical trial can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk
Types, costs, preparation, results explained
Similar content being viewed by others Background Chronic obstructive pulmonary disease (COPD) is a significant public health problem worldwide and the third leading cause of death in the United States [1]